MIRA INFORM REPORT

 

 

Report Date :

06.01.2014

 

IDENTIFICATION DETAILS

 

Name :

DR. LAZAR Y CIA.S.A. QUIMICA E INDUSTRIAL

 

 

Registered Office :

Ayacucho 318, Ciudad de Buenos Aires, República

 

 

Country :

Argentina

 

 

Financials (as on) :

31.12.2011

 

 

Date of Incorporation :

26.12.1942

 

 

Legal Form :

Limited Company

 

 

Line of Business :

·         Medicinal products for human use

·         Pharmaceutical products

 

 

No. of Employees :

390

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

No complaints

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – September 30, 2013

 

Country Name

Previous Rating

(30.06.2013)

Current Rating

(30.09.2013)

Argentina

B1

B1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

ARGENTINA - ECONOMIC OVERVIEW

 

Argentina benefits from rich natural resources, a highly literate population, an export-oriented agricultural sector, and a diversified industrial base. Although one of the world's wealthiest countries 100 years ago, Argentina suffered during most of the 20th century from recurring economic crises, persistent fiscal and current account deficits, high inflation, mounting external debt, and capital flight. A severe depression, growing public and external indebtedness, and an unprecedented bank run culminated in 2001 in the most serious economic, social, and political crisis in the country's turbulent history. Interim President Adolfo RODRIGUEZ SAA declared a default - at the time the largest ever - on the government's foreign debt in December of that year, and abruptly resigned only a few days after taking office. His successor, Eduardo DUHALDE, announced an end to the peso's decade-long 1-to-1 peg to the US dollar in early 2002. The economy bottomed out that year, with real GDP 18% smaller than in 1998 and almost 60% of Argentines under the poverty line. Real GDP rebounded to grow by an average 8.5% annually over the subsequent six years, taking advantage of previously idled industrial capacity and labor, an audacious debt restructuring and reduced debt burden, excellent international financial conditions, and expansionary monetary and fiscal policies. Inflation also increased, however, during the administration of President Nestor KIRCHNER, which responded with price restraints on businesses, as well as export taxes and restraints, and beginning in 2007, with understating inflation data. Cristina FERNANDEZ DE KIRCHNER succeeded her husband as President in late 2007, and the rapid economic growth of previous years began to slow sharply the following year as government policies held back exports and the world economy fell into recession. The economy in 2010 rebounded strongly from the 2009 recession, but has slowed since late 2011 even as the government continued to rely on expansionary fiscal and monetary policies, which have kept inflation in the double digits. The government expanded state intervention in the economy throughout 2012. In May the Congress approved the nationalization of the oil company YPF from Spain's Repsol. The government expanded formal and informal measures to restrict imports during the year, including a requirement for pre-registration and pre-approval of all imports. In July the government also further tightened currency controls in an effort to bolster foreign reserves and stem capital flight

 

Source : CIA

 

 


company name and address

 

DR.LAZAR Y CIA.S.A. QUIMICA E INDUSTRIAL

CUIT.: 30-50119062-0

 

 

 Summary 

 

INCORPORATED IN 1942. BEGINNER OF ACTIVITIES. BALANCE AS OF 31/12/2011(LAST KNOW): NORMAL POSITION ECONOMIC/FINANCIAL. RESULTS POSITIVE OF DISCREET MEANING. IT DOESN´T REGISTER NEGATIVE ANTECEDENTS. FIT FOR NEW CREDITS WITH GUARANTEES.

 

 

 

 Operations 

 

MEDICINAL PRODUCTS FOR HUMAN USE
PHARMACEUTICAL PRODUTS
MANUFACTURE
COMMERCIALIZATION

 

 

 

 Legal Structure 

 

Business type:          Limited Company
Incorporated:            26/12/1942
Registered:              18/03/1943
Duration:                   99 years
End of fiscal year:     31/12

 

 

Contact 

 

Dr. Alejandro Goya (Administrative Management).

Legal Address: Ayacucho 318, Ciudad de Buenos Aires, República Argentina.

Headquarters: Velez Sarsfield 5855, Munro, Provincia de Buenos Aires, República Argentina.

Phone/fax: (54-11) 5550-2900

E-mail: info_lazar@lazr.com.ar
      aegoya@lazar.com.ar

 

 

Partners 

 

President:             ZIFFER ANDRES DANIEL
Vicepresident:       SUARDI LUIS MARIA
Director:                WAISSMANN DE REWALD MARGARITA
Alternate Director:  ZIFFER ELENA RUTH

The president and v.president are in charge of the direction and administration of the company and, as Managers, have use of signature indistinctly.

 

 

Corporate Stock 

 

The share capital is established in $ 2.412.700 suscribed and paid in from which 99,73% is contributed by the parent company:

FAGLU S.A.C.I.F.I.
Ayacucho 318, Ciudad de Buenos Aires.

 

 

Personal Information 

 

ZIFFER ANDRES DANIEL:
Argentinean, married in second time with Ana María Garzelli, Business Administration, Born in 29/10/1959, DNI.No. 13.512.089 (CUIT No.20-13512089-9) Address at Pte.Roca 353, Beccar, Pcia.de Buenos Aires.

He registers antecedents in the following companies:

> HEDAZI S.A.                                  President
> LOS LUPINES S.A.                        President
> FARMALINK S.A.                           Director
> FAGLU S.A.                                    Director
> LA CARLOTA S.A.                          Director
> UNION CIENTIFICA BELGO ARGENTINA SA. Vicepresident

SUARDI LUIS MARIA:
Argentinean, married, born in 30/03/1933, Lawyer Dr. , LE.No. 4.097.661 (CUIT No.20-040661-3) address at Pedro Moran 3510, Cdad.de Buenos Aires.

He registers antecedents in the following companies:

> FAGLU S.A.                               President
> GRISSE COMPANY S.A.           Alternate Director
> BENVENUTO S.A.C.I.                 Trustee

 

 

History 

 

While the incumbent directors are rare in the particular details, being for information before nuestor power, states that in order to address the representation of products imported by mid-1934 the firm was constituted LABORATORIES LAZAR SH , whose power lasted until the end of 1942.

At that time, by mutual agreement between the parties concerned, arises as to continue the business under review and that, for the purposes provided it is established in the directions that opportunity.

 

 

Economic-Financial Position 

 

Continued with the policy of not provided financial information.

 

 

Balance Sheet 

 

Balance Sheet/s

31/12/2011

31/12/2010

Total Assets

$ 94.597.210,00

$ 70.300.744,00

Current Assets

$ 83.911.976,00

$ 60.372.680,00

Banks

$ 0,00

$ 0,00

Accounts Receivables

$ 0,00

$ 0,00

Inventory

$ 42.502.593,00

$ 26.088.746,00

Fixed Assets

$ 0,00

$ 0,00

Non-Current Assets

$ 10.685.234,00

$ 9.928.064,00

Investments

$ 0,00

$ 0,00

Total Liabilities

$ 48.668.123,00

$ 30.137.787,00

Current Liabilities

$ 46.082.596,00

$ 26.496.815,00

Non-Current Liabilities

$ 2.585.527,00

$ 3.640.972,00

StockHolders Equity

$ 45.929.087,00

$ 40.162.957,00

Net Sales

$ 153.505.689,00

$ 120.326.325,00

Cost of Good Sold

$ 75.393.342,00

$ 63.478.233,00

Gross Result

$ 78.112.347,00

$ 56.848.092,00

Administrative Expenses

$ 8.903.055,00

$ 7.427.076,00

Selling Expenses

$ 57.697.997,00

$ 43.011.487,00

Financial Income

$ 0,00

$ 0,00

Other Expenses

$ -5.189.165,00

$ -2.131.225,00

Final Result

$ 6.322.130,00

$ 4.278.304,00

 

 

Balance Sheet Analysis 

 

Indexes

31/12/2011

31/12/2010

Current Ratio

182,09 %

227,85 %

Quick Ratio

89,86 %

129,39 %

Short Term Indebtedness

100,33 %

65,97 %

Debt to Equity Ratio

105,96 %

75,04 %

Long Term Assets to Total Assets

11,30 %

14,12 %

Fixed Assets to Equity

0,00 %

0,00 %

Total Assets to Total Liabilities

194,37 %

233,26 %

Debt Ratio

51,45 %

42,87 %

Equity Ratio

48,55 %

57,13 %

Investments to Assets Ratio

44,93 %

37,11 %

Current Investment

88,70 %

85,88 %

Stocks Aging Days

205,77 días

150,01 días

Day Sales

0,00 días

0,00 días

Trade Debtors To Assets

0,00 %

0,00 %

Total Assets Turnover

162,27 %

171,16 %

Net Worth Aging

334,22 %

299,60 %

Fixed Assets Aging

Infinito %

Infinito %

Gross Profit

49,11 %

52,76 %

Financial Expenses on Sales Ratio

0,00 %

0,00 %

Commercial Exp. on Sales Ratio

37,59 %

35,75 %

Administrative Exp. on Sales Ratio

5,80 %

6,17 %

 

 

Assets 

 

REAL ESTATE:
------------
Avda.Velez Sarsfield 5855, Carapachay, Prov.de Buenos Aires, OF INTERESTING MARKET VALUE.

VEHICLES:
---------
7 MOVIL UNITS DEDICATED TO ITS OPERATIONS Volvo, Volkswagen, Peugeot, Fiat AND Iveco.  NO MORE DETAILS AVAILABLE.

 

 

 Evolution and Results 

 

Company renowned and important in its sector, has to do with laboratory equipped with modern technology, according to the demands of a highly competitive market, in whose care managers are responsible together with the necessary staff.

Throughout its history the company grew to support the pharmaceutical and clinical research to the development and synthesis of new molecules, constantly adding new products to its line and providing invaluable therapeutic elements in the fight against the most diverse conditions.

With a past of hierarchy and a modern present, the company currently has an industrial model, which makes synthesis of drugs for own production, for export and for third parties with which rersponden processing areas to the most advanced and demanding standards international quality standards.

Numerous of own brand products elaboration, among which may be mentioned the following:

ADIUVAN MET              NOVURIT
DERMOTOPIC             SIMULTAN A
REGULACID                RESTINIL
RIFAMPICINA              SUPLIGOL NF
TALIDO9MIDA LAZAR  TOMOXIFENO LAZAR
TEURIPAR                    XICLOVIR
NEUROLAZ                    PARATROPINA
PARACETAMOL LAZAR        RANITIDINA LAZAR
FLOGISILIN               GLUKENIL
LACTULON               LIPONORM
MEDOBIS                CIPROFLOXACINA LAZAR
DILUTOL                  FANALETAS
ALFADIMAN             ARZIMOL

FOREIGN TRADING:
----------------
In the last 12 months of management has made imports for u$s 2.255.872 from the following countries:

SOUTHAFRICA               590.420
ITALY                               530.217
HUNGARY                      246.378
OTHERS                          888.857

The main imports were:

Heterocyclic compounds.
Chemically pure sugars.
Aluminum Sheet and Strip laboratory.

MAIN SUPPLIERS:
---------------
> PLASTINORT S.A.
> IMPREFIN S.A.
> HERTWELL S.A.
> BELSTORE

* 390 employees

 

 

Payment Record and Credit Risk 

 

BANCO DE LA PROV.DE BS.AS.
BANCO DE LA NACION
BANCO
DE GALICIA Y BS.AS.
BBVA BANCO FRANCES

INSURANCES:
-----------
ZURICH CIA.DE SEGUROS S.A.
CHUBB SEGUROS S.A.
ALLIANZ CIA DE SEGUROS S.A.

CREDIT RISK:
------------
OCTOBER 2013

BANCO FRANCES    $ 5.434.200
 CREDICOOP       3.505.700
 SANTANDER       757.000
AMEX                   7.000
 GALICIA              1.400
PCIA. BS. AS.      700

Situation 1: normal.

 

 

Concept 

 

At present there is no record of any indole negative that may affect our business concept of informed and determined through the checks that maintains proper conduct in the care of general obligations assumed.

* NO OBJECTIONS.

 

 

Final Opinion 

 

This society is considered suitable for new current credits in the conditions of the field.

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.62.41

UK Pound

1

Rs.102.54

Euro

1

Rs.85.20

 

 

INFORMATION DETAILS

 

Report Prepared by :

NIS

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.